Spartan Bioscience Gets CE IVD Mark for 'Sample-to-Answer' CYP2C19 Testing Platform | GenomeWeb

By Ben Butkus

This article was originally posted on Dec. 20.

Canada's Spartan Bioscience said this week that its CYP2C19 molecular test, which runs on the company's Spartan Rx PCR-based point-of-care testing platform, has received a CE Mark for in vitro diagnostic use in Europe.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.